Statistics
Publications
3
Citations
37
H-Index
3
Active since
2020
Affiliations
Inserm(Current)
Liang Lu is an author at Inserm specializing in programmed death-ligand 1 inhibitors, pd-l1 blockade, and cancer immunotherapy.
Publications per year
2020–2025
3
3
CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
Li Fu, Jingrong Li, Ke Yin et al. · Acta Pharmacologica Sinica · 2020 · 11 citations · Full text
Pharmacy, Immunology, Oncology +16
1–3 of 3